These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33540760)

  • 1. BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia.
    Seipel K; Kopp B; Bacher U; Pabst T
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
    Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.
    Seipel K; Schmitter K; Bacher U; Pabst T
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31718075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Mandhair H; Bacher U; Pabst T
    Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Kohler S; Bacher U; Pabst T
    Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
    Nishida Y; Maeda A; Kim MJ; Cao L; Kubota Y; Ishizawa J; AlRawi A; Kato Y; Iwama A; Fujisawa M; Matsue K; Weetall M; Dumble M; Andreeff M; Davis TW; Branstrom A; Kimura S; Kojima K
    Blood Cancer J; 2017 Feb; 7(2):e527. PubMed ID: 28211885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling.
    Valiulienė G; Vitkevičienė A; Skliutė G; Borutinskaitė V; Navakauskienė R
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
    Maeda A; Nishida Y; Weetall M; Cao L; Branstrom A; Ishizawa J; Nii T; Schober WD; Abe Y; Matsue K; Yoshimura M; Kimura S; Kojima K
    Oncotarget; 2018 Jun; 9(47):28547-28560. PubMed ID: 29983879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
    Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
    Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
    Ragon BK; Odenike O; Baer MR; Stock W; Borthakur G; Patel K; Han L; Chen H; Ma H; Joseph L; Zhao Y; Baggerly K; Konopleva M; Jain N
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):431-440.e13. PubMed ID: 31056348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
    Kowolik CM; Lin M; Xie J; Overman LE; Horne DA
    Oncotarget; 2016 Dec; 7(52):86186-86197. PubMed ID: 27863389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.
    Heuser M; Beutel G; Krauter J; Döhner K; von Neuhoff N; Schlegelberger B; Ganser A
    Blood; 2006 Dec; 108(12):3898-905. PubMed ID: 16912223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
    Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
    Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.